Regeneron Reports Third Quarter 2020 Financial and Operating Results
The Pharma Data
NOVEMBER 5, 2020
FDA accepted for priority review Libtayo ® (cemiplimab-rwlc) for both advanced non-small cell lung cancer and basal cell carcinoma. FDA approved Inmazeb for Ebola ( Zaire ebolavirus). NASDAQ: REGN ) today announced financial results for the third quarter of 2020 and provided a business update. government. 30%. *. *.
52 
Let's personalize your content